3/12/2014 9:15:20 AM
NEW YORK and LONDON, March 11, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that it held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on February 12th, 2014, to discuss the regulatory pathway for the development of MRX-6 cream in atopic dermatitis, also known as eczema, an inflammatory skin disorder affecting 5% to 20% of children world-wide. The Company plans to file the IND for MRX-6 with the FDA in the fourth quarter of 2014, and initiate Phase II trials in the US in the first half of 2015.
Help employers find you! Check out all the jobs and post your resume.
comments powered by